RE:RE:RE:Why the delay? Thanks all and for the table DJD - glad to know that not alone in being unable to make sense of things to date and hope that we may yet be pleasantly surprised by elements of this imminent report.
Yes CS/stocksnbonds the ‘signal’ as to where we are headed will only really come from the double-optimised treatments so there is an element of a Trial within a Trial.
It was not an easy setting to begin with and the mis-dosing at the start of Phase II must have made it difficult to report while maintaining ability to include numbers of enrolees for the Breakthrough Designation and at times even a rationale for the continuation of the Trial itself. So there is sympathy for the Company as it seeks to nurse the Trial through to ‘normalised’ data from ‘optimised’ treatments but this is not mutually exclusive to the clear and comparable presentation of data that needs to be demonstrated in the forthcoming quarterly.